Stay updated on Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial page.

Latest updates to the Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded a dedicated Locations section featuring Pennsylvania as a location, replacing the old Pennsylvania Locations header. Removed the HHS Vulnerability Disclosure footer link and updated the page revision from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 in the release notes/footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check54 days agoChange DetectedRemoved the general government funding operating status notice from the page; the core trial content and data remain unchanged.SummaryDifference0.4%

- Check68 days agoChange DetectedThe page shows minor UI/layout updates with no modification to core study information. Eligibility criteria, endpoints, and results remain unchanged.SummaryDifference0.4%

- Check97 days agoChange DetectedAdded a government funding status notice and NIH Clinical Center operating status guidance; updated version to v3.2.0 (removing v3.1.0).SummaryDifference4%

- Check104 days agoChange DetectedMajor update: new version v3.1.0 with expanded immune system terminology and related entities; old version v3.0.2 removed.SummaryDifference1%

Stay in the know with updates to Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial page.